SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Helus Pharma (HELP) Reports Positive Phase 3 MDD Trial Results

Helus Pharma reported HLP003 reduced MADRS scores versus placebo by 7.6 points at Week 6 and 7.0 points at Week 12 in the Phase 3 APPROACH trial; both differences were statistically significant (p<0.0001).Material DetailsContext by AI AnalystThis is an early-stage clinical catalyst: positive toplin…

HELP

Related stories